Section 06 — answers about recovery and rules
What TB-500 recovery claims can leave you wondering
Returning pain can leave you unsure which claims to trust. These answers explain what tests found and why larger-protein results don't establish help from the small part.
What the name tells you, and why the short part differs
What TB-500 matches in the larger protein
TB-500 matches parts 17 to 23 of thymosin beta-4, which helps cells move [1]. TB-500 is man-made and used for research and animal work. It has no approval to treat your illness [11]. Your wish for relief still needs evidence from people given that short part.
What TB-500 letters and numbers identify
The letters refer to thymosin beta-4. Research papers and product descriptions use TB-500 to name the man-made part. The part comes from thymosin beta-4, but the number gives no treatment amount.
What TB-500 researchers hope to repair
Animal tests and tests on cells in dishes examine wounds, hearts, and brains [5]. Thymosin beta-4 and its actin-holding part are of interest because cells need to move during repair. Actin, a protein inside cells, supports that movement. The tests also examine scars and new blood vessels.
What TB-500 has yet to show inside a person
Thymosin beta-4 holds actin, supporting the shape of cells as well as their movement [1][2]. The proteins join 1:1, with one holding the other. Keeping some actin ready helps cells reshape themselves during repair. The seven-part piece hasn't proved those effects in people.
Why TB-500 works differently from a steroid, if it works
TB-500 has seven linked amino acids, each a small building block of proteins [1]. A steroid has four rings: tiny chemical parts called atoms join into loops. Steroids affect cells that respond to hormones, the messages carried around your body. The small piece's proposed effects concern cell movement and repair instead. That difference doesn't prove the short part works or is safe.
What healing tests still cannot answer for your body
How easing swollen tissue with TB-500 remains unproved
These lab findings used whole thymosin beta-4, rather than the small piece in people. The protein reduced activity starting inflammation, the body's response to injury [13]. Other work found the protein helping that response end [14]. You don't have human proof of pain relief from TB-500.
How TB-500 might affect your immune defenses remains unknown
Your immune system protects you, but sometimes attacks healthy tissue. Thymosin beta-4 appears to help inflammation end, rather than provoke those attacks [14]. Human tests haven't established help or harm to your defenses from the short part.
Why TB-500 has no human proof of muscle strength
A six-month study used mice with inherited muscle disease [5]. Thymosin beta-4 brought muscle-forming cells toward injury, and more newly repaired fibers appeared. Yet the mice weren't stronger and their hearts worked no better. TB-500 hasn't had human comparison tests of recovery after exercise.
How closing human wounds with TB-500 remains untested
Animal wounds and eye-treatment studies used whole thymosin beta-4 [3][5]. Findings included more new skin, faster wound closing, and more blood vessels and collagen. Collagen is a protein giving skin strength. Human wound healing with the short part remains unproved.
Why TB-500 cannot tell you when your wound will close
Human tests haven't established a healing time for the short part. Rats given thymosin beta-4 grew 42% more new skin at 4 days and up to 61% more at 7 days [3]. The comparison rats received salt water instead of the protein. You can't use rat healing times to set your treatment times.
Why a joint injury needs its own TB-500 healing test
Thymosin beta-4 has been studied in tissues that support joints [5]. Tendons connect muscle to bone, and ligaments help hold a joint together. Healing either tissue with the short part still lacks human proof. Your joint needs evidence about that tissue and substance.
Why TB-500 heart claims need more than a finished study
The full protein produced different results across animal tests. Thymosin beta-4 helped mouse hearts work better after researchers tied a heart artery shut [2]. Thymosin beta-4 didn't reduce pig heart injury when blood flow returned. A human heart-attack study finished without posted results [10]. The missing findings leave benefit and harm unanswered for you.
What TB-500 stroke claims borrow from rat tests
Rats received thymosin beta-4 into the belly at 2, 12, and 18 milligrams for each kilogram the rats weighed [4]. The first two amounts improved movement and tests of brain function; the largest didn't. A best amount was calculated, rather than tested in people. An earlier human heart-attack trial stopped before anyone joined [11]. That heart study gives you no stroke answer.
What TB-500 half-life claims lack in human evidence
Half-life means the time half of a given amount takes to leave the body. The small piece has no sound human test of that time. In Phase 1, an early safety study, larger thymosin beta-4 amounts took longer to clear from blood [6]. Drug detection tests don't establish that clearing time in you.
What safety findings leave unknown when you compare substances
What TB-500 safety reports cannot settle for you
Human evidence gives little help in judging the small protein part's safety. Phase 1, an early safety test, found whole thymosin beta-4 well tolerated into a vein up to 1260 milligrams [6]. That doesn't establish the small piece's safety. Growth of tumors remains a possible concern [5], and research products may contain impurities or the wrong substance.
What makes cancer a possible concern with TB-500
In the lab, work links higher thymosin beta-4 amounts in several cancers with tumors growing and spreading [5]. Cell movement and the forming of blood vessels might also help tumors. That concern hasn't been proved as harm to people given the short part.
Why TB-500 safety over years is still unknown
There are no long human safety tests of TB-500. The longest controlled exposure was a 14-day Phase 1 test of whole thymosin beta-4 into a vein [6]. A tumor might also use the cell movement and blood supply involved in repair [5][12]. Feeling well during a short test doesn't settle your risk over years.
What human testing of TB-500 is still missing
TB-500 has no finished human comparison trial for treating illness. Whole thymosin beta-4 had a Phase 1 vein-treatment study with groups picked by chance [6]. Other human work tested eye drops [7]. A heart-attack shot study finished without posted results about the patients' health [10]. An earlier heart-attack study never enrolled anyone [11]. You need findings, rather than just the fact that a study ended.
What differs when you compare TB-500 and BPC-157
These substances have different parts and different proposed actions. TB-500 matches part of thymosin beta-4, a protein involved in the movement of cells [1]. BPC-157 is a man-made chain of fifteen building blocks based on a protein present in the juices inside the stomach. That origin doesn't prove treatment for stomach trouble. Neither has drug approval, both face sport bans, and most findings come from animals.
What pharmacy rules and sport bans change for you
What TB-500 legal status does not grant
FDA hasn't approved TB-500 as a drug. In September 2023, FDA put the short part in Category 2 under section 503A, the law for pharmacies making medicine for a named patient. That group flags possible serious ingredient risks. The current page lists TB-500 among withdrawn requests, outside that group. FDA hasn't explained what a 503A patient pharmacy may now make [reg1][reg3]. Researchers use the short part, including in animal studies. WADA bans use in sport; some countries require a prescription.
The July 23–24, 2026 meeting agenda named “TB-500 (free base),” without added salt, and “TB-500 acetate,” with an acetate salt attached [reg2]. Those names distinguish pharmacy forms, rather than promise different benefits for your body. The meeting occurred, but no FDA vote report was posted as of September 2026. Talking about an ingredient doesn't approve treatment.
What a pharmacy must check beyond your TB-500 prescription
Your care starts with a licensed prescriber assessing your health [reg3][reg4]. A lawful phone or video visit can serve that purpose. A 503A patient pharmacy or 503B batch-making facility must still use allowed ingredients. Your prescription doesn't remove that separate duty.
FDA's page current as of April 22, 2026 places TB-500 among withdrawn requests, outside Category 2 [reg4]. The person filing the request took the request back. FDA still gives its safety concerns and hasn't said what a 503A patient pharmacy may make after withdrawal. These general rules can't settle your own medical question or supply treatment.
What the FDA 503A risk group meant for TB-500
FDA identified the small part taken from thymosin beta-4 as TB-500 in its September 29, 2023 update [reg1]. Section 503A concerns medicine made for a named patient. FDA put the short part in Category 2, for ingredients that may pose serious risks. Concerns included unwanted immune responses depending on how the substance enters the body, and missing safety facts.
For Category 2 ingredients, FDA doesn't promise to hold off legal action against patient pharmacies using those ingredients [reg3]. That means the temporary policy doesn't protect such pharmacy use. TB-500 now appears among withdrawn requests, rather than in that risk group. What a pharmacy may make after withdrawal remains unexplained by FDA. At the July 2026 meeting, FDA staff opposed adding the substance to the list [reg2]. As of September 2026, no FDA vote report had appeared.
What TB-500 sport bans cover away from an event
WADA governs drug use among athletes in tested sport. The rules ban TB-500 and thymosin beta-4 as substances linked to growth and repair. The ban applies during events and between events, and tests can detect the substances. A hoped-for benefit doesn't remove the ban.
What horse tests found about TB-500 use
TB-500 turned up in horse sport, prompting tests able to detect tiny amounts. Those tests showed detection in horses, rather than treatment benefit in people. Racing governed by those rules bans the substance.